|20/12/25||GEM236||Nicotinamide phosphoribosyltransferase （NAMPT） inhibitor||Hematological （AML, ALL, lymphoma, MM） and some solid tumors （sarcoma, kidney, melanoma. etc）||Oral||Small molecule||Phase 1/2a||-NAMPT is critical for the growth/survival of hematological cancers.
-Synthetic small molecule structurally unrelated to NAMPT substrate or known inhibitors. -will be the First-In-Class drug.
-Favorable pharmacological and toxicological profiles, showed no ophthalmic toxicity.
-May increase susceptibility to other targeted cancer drugs (BCL-2, PARP, tyrosine kinase, proteasome, and HDAC inhibitors, anti-PD-1 antibodies) and DNA-damaging chemo/radiotherapy. Synergizes with tumor-specific mutations (IDH1/2, PPM1D, DNA repair deficiency).
-Phase I study, which is near completion, demonstrated favorable toxicology profile with myeloid cells dose-limiting toxicity and signs of efficacy seen in several patients.
|20/12/25||GEM235||Mineral sunscreen powder||Sunscreen||Topical||Natural ingredient||Commecial||GEM235 is an easy-to-use brush applicator, filled with an effective mineral powder with SPF 50. The 100% natural formula makes GEM235 safe to use on rash-prone skin, eczema, allergy-prone skin and sensitive skin.||問合せ|
|20/12/21||GEM234||Crosstalk of TGF-β signal and Wnt/β-catenin signal||Liver fibrosis, Nonalcoholic steatohepatitis, Kidney fibrosis, Renal fibrosis, Liver cancer, COVID-19||Injection||Small molecule||Preclinical||GEM234 is a novel small molecular which has suppressive effects on both hepatic stellate cell activation and kidney and liver fibrosis by suppressing TGF-β/Smad pathway via inhibition effect of Wnt/β-catenin pathway. GEM234 shows a higher suppressive effect on liver cancer stem cells than 5-FU. Wnt/β catenin inhibitors can block the infection of SARS-Cov-2, and GEM234 has potential to prevent occurrence of ARDS and cardiovascular damage in COVID-19.||問合せ|
|20/12/21||GEM062||Anandamide（AEA）-releasing topical formulation （sustained release for about 24 hours）||Cutaneous Lupus, （and other autoimmune/ inflammatory skin conditions）||Topical||Small molecule
||Preclinical||Tissue imaging to demonstrate efficient penetration and controlled release of AEA from
AEA-loaded GEM062. Efficacy of AEA-loaded GEM062 in treating
cutaneous lesions in murine model of CLE has been demonstrated.
|20/12/21||GEM092||Androgen receptor agonist||Hypogonadism||Oral （BID）||Small molecule
||Received FDA tentative approval||A novel oral prodrug of testosterone that is designed to help restore normal testosterone levels in hypogonadal men. GEM092 was well tolerated and met the primary end-points in Phase 3 testing with twice daily dosing. Easy to use for patients and physicians to prescribe due to fixed doing regimen.||問合せ|
|20/12/04||GEM233||Inhibition of pro-cytokines, enhancement of growth factor PDGF||Diabetic foot and leg ulcers||Topical||Botanical||Phase 2 completed||-Small molecules from soybean extract.
-MOA facilitates multiple phases at molecular levels of wound healing processes.
-Effective in STZ induced diabetic wound model and cell migration quality control.
-In Phase 2 study, ulcer complete closure rate up to 12 weeks is 32.7% in GEM233 group vs 15.4% in placebo group. Subjects in the GEM233 group had an average of 73±2.9 days to achieve ≥ 90% reduction in target ulcer size.
|20/11/27||GEM232||Anti-soluble MICA/MICB antibody||Prostate Cancers （mCRPC）, other cancers||i.v.||Antibody
||Preclinical||- GEM232 is a humanized antibody specific for soluble NKG2D ligands MICA and MICB, which are multi-mechanistic suppressors of the immune system that become upregulated in cancer but are normally absent.
- GEM232 binds non-membrane bound MICA/B (shed/soluble forms) but not cell surface attached versions, thereby offering safety benefits such as avoiding autoimmunity.
- Antibody binding may help prevent immunosuppression and may enhance NK and CD8+ T cell activation mediated by the NKG2D receptor leading to tumor cell killing. Both arms of immune system (innate and adaptive) can be impacted.
- Significant tumor inhibition demonstrated using prostate xenografts in both immune compromised mice and in mice with humanized immune systems (hPBMC), with no observable toxicity. A unique epitope has been identified for this high affinity antibody.
|20/11/25||GEM231||JNK inhibitor||Dry Eye, Dry and Wet AMD, Uveitis, Chronic inflammation alternative to Steroids||Intra- vitreal, Subcon- junctival, Drops||Peptide
||Clinical Phase 3 （performed in acute post surgery）||・Potent and selective non-ATP competitive hJNK2 and hJNK3 inhibitor
・Full D amino acids – TAT peptide with high resistance to proteases and highly soluble in saline
・Coupled to a carrier sequence that selectively delivers it into the cell
・Excellent safety and toxicology profile (therapeutic indexes in 100 -1000 range)
・Administered to 1000+ patients to date with no sign of intolerance
・Excellent patent position
・Simple to manufacture at low COG per dose
|20/11/25||GEM230||Anti-CD38 scFv-Fc conjugation of lenalidomide||Multiple Myeloma||i.v.||Antibody-drug conjugates
- The conjugation does not affect cell binding affinity compared to parental antibodies.
- Conjugation with lenalidomide bundle did not affect ADCC/CDC activities on CD38+ cells
- In the multiple myeloma xenograft mouse model, GEM230 has superior tumor suppression ability compared to parental antibody, Darzalex.
|20/11/25||GEM229||Insulin with fatty acids bundle||Type1/2 Diabetes||s.c.||Peptide conjugated fatty acid
- can be produced in high quality and activate AKT phosphorylation as degludec.
- can induce cell proliferation as degludec and inhibit cell apoptosis as degludec.
-can better reduce blood glucose than degludec and effectively control blood glucose level at lower dosage than degludec.
GEM229 shows better blood glucose control than degludec by once daily injection and better blood glucose control than degludec by every other day (Q2D) injection for 30 days.
GEM229 causes a significant reduction in HbA1C level after treating for 60 days